About Ovoca Bio
Ovoca Bio is a clinical-stage biopharmaceutical company focused on women’s health. In 2018 the Company acquired control of IVIX, a biotechnology company developing Orenetide (BP-101), a novel medicinal treatment for premenopausal women with hypoactive sexual desire disorder (HSDD). Since the initial acquisition, Ovoca Bio has supported the continued clinical development and commercial planning of Orenetide, which has been submitted for marketing authorisation in Russia and has commenced a Phase II study in a western population with HSDD. In March 2020, Orenetide became a fully owned program of Ovoca Bio.
Founded and incorporated in Ireland, the business currently operates in Ireland, the UK and Russia.
Our Vision & Approach
Ovoca Bio’s vision is to become a leader in the research and development of, and commercial partner of choice for, novel medicines in areas of high unmet need that affect women.
The Company has filed for approval for the marketing of Orenetide in Russia and has commenced development of the drug for major global markets, with special focus on the US and Europe.
Ovoca Bio will consider opportunities to license commercialisation rights and/or collaborate with global pharmaceutical companies, regional partners or other qualified potential partners where they would accelerate the availability of current plus future product candidates to patients in need.
Ovoca Bio owns a patent portfolio that provides broad effective protection of its technology and lead product candidate. The Company intends to continue to leverage this patent portfolio and selectively add to it, to develop and commercialise its initial product candidate and potentially future ones.
European-based biopharmaceutical company with a focus on women’s health
Currently developing a novel synthetic peptide (Orenetide) for treatment of women with hypoactive sexual desire disorder (HSDD)
€13.6 million in cash and liquid assets to support drug development activities company with a focus on women’s health
Experienced team and top advisors to deliver on corporate goals
Chief Executive & Interim Chairman
Mr. Golovanov joined Ovoca as a corporate advisor in 2007 and was appointed Chief Executive Officer of Ovoca in May 2012. He has extensive experience in the development of venture businesses in Russia. Mr. Golovanov holds a Juris Doctor degree from the Moscow State Law Academy, Moscow, Russia and an MBA from Duke University’s Fuqua School of Business, NC, USA.
Chief Business Officer
Mr. Wiltshire is an experienced senior pharmaceutical and biotechnology executive with over 27 years of international experience. He currently serves as the Chief Executive Officer of Hematherix LLC, which is developing a recombinant clotting factor, and is former head of Business Development and Licensing at La Jolla Pharmaceutical (NASDAQ). He has a successful consultancy practice which provides strategic advice to early and mid-stage biotechnology and pharmaceutical companies. Mr. Wiltshire previously served in a number of senior positions at Pfizer, including Head of Business Transactions and Investments within The Pfizer Incubator LLC. Mr. Wiltshire holds an MA in Engineering from the University of Cambridge in the UK and an MBA from the Darden Graduate School, University of Virginia, USA.
Dr. Daniil Nemenov
SVP, Clinical Development & Operations
Dr. Nemenov joined Ovoca Bio subsidiary, Ivix Ltd. in 2014 as its Medical Director. Dr. Nemenov is managing the BP-101 clinical development program and has overall responsibility for the operations of Ivix Ltd. Dr. Nemenov holds an MD from Moscow Medical Academy and has experience as a practising medical doctor and as a pharmaceutical clinical development professional. Between 2008 and 2011, Dr. Nemenov worked in clinical research at Novartis Pharma, and has since 2011 been the clinical/medical director at several biotech start-ups, such as TheraMAB and Promogen MAB.
Dr. Mikhail Lomonosov
VP, Research & IP
Dr. Lomonosov joined Ovoca Bio subsidiary, Ivix Ltd. in 2013 and is managing the Company’s research and international Intellectual Property activities. Holding a PhD from the Russian Institute of Gene Biology, Dr. Lomonosov has broad experience in international scientific research and completed part of his PhD at the Danish Cancer Society in Copenhagen, Denmark, followed by postdoctoral training at the International Centre for Genetic Engineering and Biotechnology in Trieste, Italy. From 2000 to 2009 he conducted research in the Department of Oncology and Department of Pathology at the University of Cambridge, UK.
Dr. Alexey Matskevich
Dr. Matskevich is responsible for preclinical studies and projects to expand the pipeline. He has wide knowledge in the fields of biochemistry and immunology, molecular and cellular biology, obtained while working at the University of Zurich, Louis Pasteur University, Thomas Jefferson University, and Karolinska Institute. Dr. Matskevich has co-authored more than 55 publications, including articles published in Science, Cell and Nature Biotechnology. He holds a PhD in Biochemistry and Pathophysiology from Moscow State University and Institute of General Pathology and Pathophysiology.
Dr. Eduard Benetskiy
Dr. Eduard Benetskiy manages the drug substance and product manufacturing activities for orenetide (BP-101). He joined Ivix LLC, the Ovoca Bio subsidiary, in April 2021. Eduard holds a PhD from the Institute of Organoelement Compounds of the Russian Academy of Sciences, Moscow, Russia. He completed postdoctoral training at the RWTH Aachen University and at the Leibniz Institute for Catalysis at the University of Rostock (LIKAT), both in Germany. Eduard has more than 10 years experience working in the field of organic chemistry and catalysis and 8 years in drug development in the pharmaceutical and biotech sectors .
Mr. Nikitashenko joined Ovoca Bio in 2020 and is responsible for the administration of the Company’s financial and capital resources. He holds a double degree in Finance and International Relations from the University of Calgary, Canada and has experience from the transportation and construction industry having worked at the Canadian Pacific Railway and Custom Construction Group. Mr. Nikitashenko also held a seat on the Board of Directors at Battistella Developments’ Condominium Corporation in Calgary.
Director of Finance
Ms Kozlova is responsible for corporate finance with more than 15 years financial experience in sectors including pharmaceuticals, oil production and retail business. Over the past 8 years, she has provided financial support to biopharmaceutical development companies. Ms Kozlova graduated from the Moscow State Institute of International Relations (MGIMO) with a Masters of Finance and Acccounting.
Ms. Bendas graduated from the Faculty of Law at the Moscow State University and joined the Ovoca team. Her responsibilities include managing corporate law, contractual and litigation matters of the Ovoca group of companies.
Sofia works closely with the executive team on administrative, management and communication functions within and outside of the firm. She holds a management degree from the Labor and Social Relations Academy, Moscow, Russia.
Board of Directors
Chief Executive & Interim Chairman
Mr. Golovanov joined Ovoca as a corporate advisor in 2007 and was appointed Chief Executive Officer of Ovoca in May 2012. He has extensive experience in the development of venture businesses in Russia and leading large enterprises such as Gazprombank and Vneshekonombank. Mr. Golovanov holds a Juris Doctor degree from the Moscow State Law Academy, Moscow, Russia and an MBA from Duke University’s Fuqua School of Business, NC, USA.
Mr. Wiltshire is an experienced senior pharmaceutical and biotechnology executive with over 27 years of international experience. He currently serves as the Chief Executive Officer of Hematherix LLC, and is former head of Business Development and Licensing at La Jolla Pharmaceutical (NASDAQ). He has a successful consultancy practise which provides strategic advice to early and mid-stage biotechnology and pharmaceutical companies. Mr. Wiltshire previously served in a number of senior positions at Pfizer, including Head of Business Transactions and Investments within The Pfizer Incubator LLC. Mr. Wiltshire holds an MA in Engineering from the University of Cambridge in the UK and an MBA from the Darden Graduate School, University of Virginia, USA.
Mr. Colindres is an experienced medical practitioner and pharmaceutical executive, having worked with GlaxoSmithKline plc (“GSK”) in a number of senior roles since 2007. Mr. Colindres is currently the Vice President Global Medical Affairs Lead for Zoster with GSK and has previously held roles with GSK in Panama, Brazil and Belgium during his career. Prior to joining GSK, Mr. Colindres was a physician in the United States and Brazil, and previously held roles within public health in the United States and El Salvador. Mr. Colindres holds an MBA from Duke University’s Fuqua School of Business, NC, US, and MD from the University of North Carolina School of Medicine, Chapel Hill, NC, US and a Master of Public Health from University of North Carolina School of Public Health, Chapel Hill, NC, US.
Mr. McCutcheon joined Ovoca as a Non-Executive Director in January 2009 and was appointed Chief Executive Officer in December 2009 before stepping down in April 2012 and becoming a Non-Executive Director. Prior to Ovoca, Mr. McCutcheon was a partner at DBM Capital Partners and he also worked at several investment banks such as Bear Stearns, Aton Capital and Pioneer Investments as an award-winning equity analyst and as an investment banker Mr. McCutcheon holds a BA, Cum Laude, from Columbia College, New York and an MBA in Finance from Columbia Business School.
Mr. Skoptsov joined the board of Ovoca in June 2006 and served as the Company’s Chief Executive Officer from 2006 to 2009. Mr. Skoptsov was part of the Bioprocess Group team that owned and ran OAO “United Machinery Plants” (OMZ). He also played an active part in natural resource development prior to Ovoca. He was the Chairman of OAO Pervaya Gornorudnaya Companiya from 2001–2005, a zinc-lead asset developer. He was also the Chairman of OAO Volganeft from 2000 to 2004, a mid-tier oil producer in Russia which was sold to RussNeft. He was part of the group that vended into Ovoca Gold plc 100% of OAO Ajax – Goltsovoye. Mr. Skoptsov holds a BA, cum laude, from Moscow State University, Moscow, Russia.
Anita H. Clayton, MD, David C. Wilson Professor and Chair of Psychiatry & Neurobehavioral Sciences and Professor of Clinical Obstetrics & Gynecology at the University of Virginia has focused her clinical practice and research on major depressive disorder, mood disorders associated with reproductive-life events in women, sexual dysfunction related to illness and medications, and treatment of primary sexual disorders. She has published over 200 peer-reviewed papers, developed and validated several measurement tools including the Changes in Sexual Functioning Questionnaire (CSFQ), the Sexual Interest and Desire Inventory (SIDI), and the Decreased Sexual Desire Screener (DSDS), has been an investigator for essentially all the newer antidepressants, including medications with new MOAs and dosing paradigms, and was named to the 2019-2020 Best Doctors in America list.
Dr. Clayton co-edited Women’s Mental Health: A Comprehensive Textbook, and authored Satisfaction: Women, Sex, and the Quest for Intimacy for the general public. She is an international leader in Female Sexual Dysfunction, as President of the International Society for the Study of Women’s Sexual Health (ISSWSH), as Vice-Chair for Women’s Sexual Health for the 3rd and 4th International Consultation on Sexual Medicine (2009, 2015), on the WHO advisory committee on the ICD-11 chapter, Conditions Related to Sexual Health, and on the Scientific Program Committee for the International Society for Sexual Medicine (2020, 2018, 2016, 2014 meetings). She has served on the board of directors for the American Society for Clinical Psychopharmacology, and as Program Committee Co-Chair (2018 and 2019).
Professor Annamaria Giraldi is Senior Consultant in Psychiatry in the Sexological Clinic at Psychiatric Center Copenhagen and Professor in Clinical Sexology at the University of Copenhagen, Denmark, where she also received her medical degree and PhD.
Professor Giraldi has been involved in the field of sexual medicine for many years, educating medical students, nurses, physicians and psychologists in sexual medicine.
Professor Giraldi has been involved in basic research on vascular and smooth muscle function in male and female sexual responses, clinical research on the pharmacological treatment of erectile dysfunction and female sexual desire and arousal disorders as well as in research on somatic disease, psychiatric problems and sexuality.
Clinically Professor Giraldi works with men, women and couples with sexual dysfunctions and has worked with transgender care. Her special academic and clinical interest is disease and sexual function and dysfunction
Professor Giraldi has published more than 100 papers, editorials and book chapters in the field of male and female sexual medicine. She is past Deputy Editor of the Journal of Sexual Medicine and President of the International Society for Sexual Medicine.
Dr. Sheryl Kingsberg is the chief of the division of behavioral medicine at MacDonald Women’s Hospital/University Hospitals Cleveland Medical Center and Professor in Reproductive Biology and Psychiatry at Case Western Reserve University. Her areas of clinical specialization include sexual medicine, female sexual disorders, menopause, pregnancy and postpartum mood disorders, and psychological aspects of infertility.
Dr. Kingsberg’s primary research interests are in treatments for female sexual disorders and genitourinary syndrome of menopause (GSM). She has been the principal investigator for several clinical trials for treatments for female sexual disorders and consults for many pharmaceutical companies that are developing investigational drug treatments for sexual problems. She is an Associate Editor for Sexual Medicine Reviews and sits on the editorial boards of the journals Menopause and Climacteric.
Dr. Kingsberg is a past president of The North American Menopause Society and The International Society for the Study of Women’s Sexual Health.
Dr Nappi is a gynecologist, endocrinologist and sexologist, and Full Professor of Obstetrics and Gynecology, Chief of the Research Center for Reproductive Medicine and Gynecological Endocrinology-Menopause Unit, IRCCS San Matteo Foundation at the University of Pavia in Italy.
Her major interests are psychoneuroendocrinology of female reproductive life and women’s sexuality. She has published more than 300 scientific articles in peer-reviewed journals and international books with 14500 citations (HF Google Scholar 66).
She is a well-known speaker on women’s health from adolescence to menopause. She has been very active in many international meetings and research projects in the field of contraception, menopause and female sexual dysfunction.
She is past president of the International Society for the Study of Women Sexual Health (ISSWSH) (2007-2008) and actual President of the Italian Society of Psychosomatic Obstetrics and Gynecology (SIPGO). At present, she is permanent member of the advisory board of the International Society of Gynecological Endocrinology (ISGE) and member of the board (General Secretary elected) of the International Menopause Society (IMS) (2018-20).
Dr. Stahl has held faculty positions at Stanford University, the University of California at Los Angeles, the Institute of Psychiatry London, the Institute of Neurology London, and, currently, as professor at the University of California Riverside, the University of California San Diego and as Honorary Fellow in Psychiatry at the University of Cambridge. Dr. Stahl serves as editor-in-chief of CNS Spectrums. Author of over 550 articles and chapters with an H index of 62, and more than 1800 scientific presentations and abstracts, Dr. Stahl is an internationally renowned clinician, researcher and teacher in psychiatry with subspecialty expertise in psychopharmacology. Dr. Stahl has written 44 textbooks and edited 14 others, including the best-selling and award winning textbook, Stahl’s Essential Psychopharmacology, now in its fourth edition and the best-selling and award-winning clinical manual, Essential Psychopharmacology Prescriber’s Guide, now in its fifth edition. Dr. Stahl has also published a novel, Shell Shock, a thriller that recounts the history of PTSD (post traumatic stress disorder). Dr. Stahl is Senior Academic Advisor and Director of Psychopharmacology for the California Department of State Hospitals (DSH) where he has a leadership role in addressing violence and decriminalization of the seriously mentally ill in the five-hospital 6500 patient DSH. He has been awarded the International College of Neuropsychopharmacology (CINP) Lundbeck Foundation Award in Education for his contributions to postgraduate education in psychiatry and neurology. His books have won the British Medical Association’s Book of the Year Award and recently, first prize for best digital medical book. Dr. Stahl is also the winner of the A.E. Bennett Award of the Society of Biological Psychiatry, the APA/San Diego Psychiatric Society Education Award, the UCSD Psychiatry Residency Teaching Award, and has been cited as both one of “America’s Top Psychiatrists” and one of the “Best Doctors in America.” He was honored with the Distinguished Psychiatrist Award of the APA and gave the Distinguished Psychiatrist Lecturer for 2013. He was named the 2016 David Mrazek Award Winner of the American Psychiatric Association and gave the Mrazek Pharmacogenomics Memorial Lecture at the 2016 APA meeting. His alma mater Northwestern University honored him by naming the award for the most promising medical student to go into psychiatry the “Stephen Stahl Award.” In 2018 he was awarded an Honorary Doctorate of Science by Üsküdar University in Istanbul Turkey for his lifetime of achievements in psychiatry. He has recently cofounded a School of Psychopharmacology, Psychiatry and Neuroethics at the European University of Rome at the invitation of the Vatican to work with Pope Francis to develop education and policies to improve the burden of the seriously mentally ill.